mRNA expression data reported by Burstein et al. [39], which subcategorize TNBC into the 4 classes described above, confirm that ACSL4 mRNA is differentially expressed in TNBC as a function of AR status, with highest expression in mesenchymal breast cancers. This evidence concerns the gene AR and breast carcinoma.